NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Spruce Biosciences, Inc. (SPRB) Stock Analysis

Spruce Biosciences, Inc. (SPRB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SPRB

$42.73

+$1.50 (+3.64%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SPRB with… →

SPRB Key Statistics

As of Oct 21, 2026
Trading
Open
$41.21
Previous Close
$41.23
Day's Range
40.82–42.73
52-Week Range
38.06–144.00
Volume
61.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.30
Valuation
Market Cap
$122.81M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
8.59
EPS (ttm)Profit attributable to each share over the last twelve months.
−39.12
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$38.97M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.87M
1-Year Return
−67.01%
Dividend and dates
Avg Volume
78.59K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SPRB closed at $42.73, −67.01% over 1 year.

Spruce Biosciences, Inc. (SPRB) has a market capitalization of $122.81M.

In fiscal 2025, SPRB reported revenue of $0.00.

SPRB Stock Return by Calendar Year

Spruce Biosciences, Inc. (SPRB) return since Oct 2020: what $10,000 became

1 year
$10,000 $3,299
−67.01%
5 years
$10,000 $17
−99.83%
Since Oct 2020
$10,000 $4
−99.96%

If you had invested $10,000 in Spruce Biosciences, Inc. (SPRB) at the close on October 9, 2020, the earliest close on record here, it would have been worth $4 at the close on October 21, 2026: −99.96% in total, −72.16% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−50.95%
2025−96.31%
2024−85.67%
2023+167.09%
2022−75.40%
2021−81.65%
2020 (partial year)+43.00%

As of October 21, 2026.

SPRB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$38.97M—
2024$4.91M−$53.04M−1,079.9%
2023$10.09M−$47.92M−475.0%
2022$0.00−$46.18M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$36.51M−$38.97M—
2024$4.91M—−$56.15M−$53.04M−1,079.9%
2023$10.09M—−$51.99M−$47.92M−475.0%
2022$0.00—−$47.28M−$46.18M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Spruce Biosciences, Inc. (SPRB) carries a market capitalisation of $122.81M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 22 employees.

The most recent close on file for SPRB is $42.73, dated October 21, 2026. That is +$1.50 (+3.64%) against the previous close. The 52-week range on file runs from $38.06 to $144.00. The latest close sits 12.27% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Against the prior fiscal year total of $4.91M, that is a change of −100.00%. The same year closed with a net loss of $38.97M. Earnings per share on a trailing basis come to −39.12.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 8.59.

Over the trailing twelve months the total return is −67.01%. Across 5 years the annualized return works out at −72.17%. Beta against the wider market is reported at 3.3. Annualized volatility over the trailing 6 years is 576.22%.

Growth & Income

The record shows no dividend for SPRB.

The strongest complete calendar year on file is 2023 at +167.09%; the weakest is 2025 at −96.31%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −50.95% year to date.

Peer Comparison

Spruce Biosciences, Inc. (SPRB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Spruce Biosciences, Inc. SPRB $122.81M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Spruce Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Visit website →